The HSD17B8 Knockout NCI-H1975 Polyclonal Cells product comprises a polyclonal population of NCI-H1975 human lung adenocarcinoma cells generated by CRISPR/Cas9-mediated disruption of the HSD17B8 gene. This polyclonal knockout pool provides a genetically heterogeneous loss-of-function model suitable for studying the collective impact of HSD17B8 ablation on mitochondrial fatty acid synthesis and steroid hormone metabolism in EGFR-mutant NSCLC.
The NCI-H1975 cell line, derived from the pleural effusion of a female lung adenocarcinoma patient, is a standard model for EGFR-mutant non-small cell lung cancer harboring the activating L858R and T790M gatekeeper mutations. These mutations confer partial sensitivity to first-generation EGFR TKIs and drive acquired resistance, making the line invaluable for studying drug resistance mechanisms. As an epithelial adenocarcinoma line, NCI-H1975 exhibits oncogenic signaling and metabolic reprogramming typical of aggressive NSCLC.
HSD17B8 encodes a mitochondrial 3-ketoacyl-CoA reductase that catalyzes the NADH-dependent conversion of 3-ketoacyl-CoA to 3-hydroxyacyl-CoA, a key step in the mitochondrial fatty acid synthesis (mtFAS) pathway. This pathway is essential for the biosynthesis of lipoic acid, a cofactor for pyruvate dehydrogenase and ??-ketoglutarate dehydrogenase, and for the assembly of respiratory chain complexes I, II, and III. Additionally, HSD17B8 possesses 17-beta-hydroxysteroid dehydrogenase activity, regulating the interconversion of estrone and estradiol. Transcription of HSD17B8 is governed by PPARGC1A (PGC-1??) and ESR1 (ER??), connecting its expression to mitochondrial biogenesis and estrogen signaling. The HSD17B8 protein interacts with the mtFAS enzymes OXSM and MECR and the acyl carrier protein NDUFAB1, positioning it at the nexus of mtFAS and respiratory chain assembly. Consequently, loss of HSD17B8 disrupts lipoic acid production, impairs respiratory function, and alters estrogen metabolism.
In NCI-H1975 cells, HSD17B8 knockout is expected to compromise mtFAS, leading to deficient lipoic acid synthesis and mitochondrial respiratory dysfunction, which may sensitize cells to metabolic stress and alter their proliferative capacity. This model provides a unique system to investigate how mtFAS inhibition impacts EGFR-mutant NSCLC, particularly in the context of TKI resistance where mitochondrial reliance may be heightened. The parallel disruption of estrogen metabolism through HSD17B8??s dehydrogenase activity introduces an additional layer of hormone-dependent modulation, allowing exploration of cross-talk between mitochondrial metabolism and steroid receptor signaling in cancer progression and drug response.
Researchers may apply this model in diverse assays, including Western blotting and RT-qPCR for knockout confirmation, Seahorse XF Mito Stress Tests for respiratory profiling, and LC-MS-based quantification of lipoic acid or steroid hormones. Cell viability and Annexin V apoptosis assays combined with EGFR inhibitors such as osimertinib or erlotinib enable drug sensitivity screens, while metabolic flux analysis can trace fatty acid utilization. This polyclonal knockout population is a versatile tool for uncovering mtFAS-dependent vulnerabilities in EGFR-mutant lung adenocarcinoma. For further technical information, please contact Ascent Research.
